Navigation Links
Alphavirus-based vaccine may slow some cancers
Date:8/2/2010

DURHAM, N.C. An experimental vaccine based on a virus that causes encephalitis in the wild appears to block tumor growth in some cases of advanced cancer, according to researchers at Duke University Medical Center. Scientists say the vaccine is able to stimulate an immune response, even in the face of profound immune system suppression, a condition most patients with advanced cancer experience.

Scientists removed the genes that enable the Venezuelan equine encephalitis virus - an alphavirus - to replicate itself, and replaced them with genes that make the biomarker CEA, present in many malignant colon, breast and lung cells.

"Alphaviruses have been used before in designing treatments for infectious diseases, but we believe this is the first time one has been used in patients with cancer," said Michael Morse, MD, associate professor of medicine at Duke and the lead author of the study appearing online in the Journal of Clinical Investigation.

The Phase I/II study included 28 patients with advanced cases of lung, colon, breast, appendix or pancreatic cancers who had already been treated with multiple courses of chemotherapy, but whose cancers kept coming back.

Cancer vaccines, unlike traditional vaccines, are designed to boost the body's own immune system to recognize and destroy tumors, not prevent disease. Scientists often use genetically altered viruses as vaccines, stripping the virus of any harmful parts and inserting genes related to their anticancer strategy. But in many cases, the immune system still sees the incoming virus as a foreign invader and springs into action, generating antibodies and T cells that destroy it before it has a chance to do any good.

Based on earlier research, investigators at Duke believed that by using the alphavirus for Venezuelan equine encephalitis as a carrier they might be able to thwart that response.

"The beauty of alphaviruses is that they are naturally attracted to dendritic cells, cells that stimulate the production of large numbers of T cells and antibodies," says Morse. "Essentially, we were hoping that once infected, the dendritic cells would activate T cells and antibodies to go after anything that had the tumor antigen CEA on it - in this case, the quickly growing cancer cells."

Participants received up to four injections plus booster shots of the vaccine over a period of three months. At the end of the study, two patients with no evidence of disease remained in remission; two patients were able to maintain stable disease, and one patient with pancreatic cancer saw a lesion in his liver disappear. The other patients in the trial did not respond to the therapy.

"Remember, these were patients with very advanced disease that nothing else had been able to stop," says Morse, a member of the Duke Comprehensive Cancer Center and a specialist in vaccine design. "We believe that in this small number of patients, the vaccine was able to stimulate the body's defense system to destroy significant numbers of cancer cells despite the presence of an army of neutralizing antibodies and regulatory T cells."

Morse says those who seemed to benefit the most were those who had the smallest amount of tumor. Because of this, he says his team is planning future trials that will test the vaccine in people with cancers that have been removed, but who are high risk of recurrence. Other trials will couple the vaccine with additional immune system stimulants such as interleukin-12 that may make the vaccine more powerful.


'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-660-1306
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Vaccine May Prevent TB in People With HIV
2. Vaccine Not Fail-Safe in Ongoing Mumps Outbreak
3. New strategy produces promising advance in cancer vaccines
4. Screens, Vaccine for HPV Less Beneficial in Older Women
5. New Technology Could Widen Reach of Vaccines
6. Texas-based consortium announces groundbreaking vaccine research program
7. The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies Failure to Provide Adequate Safety Research
8. Possible vaccine for mesothelioma proven safe
9. Groundbreaking research to find vaccine for hepatitis C
10. Vaccine for Asbestos-Related Cancer Looks Safe
11. CDC Awards Abt Associates Additional Contracts to Evaluate Effectiveness of H1N1 Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... ... exhibitor at Molecular Medicine Tri-Conference February 20 – 22 in San Francisco. As ... showcase its anatomic and molecular pathology workflow solution, as well as its new ...
(Date:2/17/2017)... ... 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from around the ... - 23 in Beaver Creek, CO. It was announced today by Cindy Lovelace, executive ... Beaver Creek, hosting over 60 faculty members and addressing unmet needs of the NET ...
(Date:2/17/2017)... ... February 17, 2017 , ... Dillon Ruxton ... families and business owners in the greater Fort Lauderdale metropolitan region, is embarking ... For more than 30 years, LifeNet 4 Families has provided a broad range ...
(Date:2/16/2017)... ... February 17, 2017 , ... For some cancer ... their final treatments. Physician researchers at The Marcus Institute of Integrative Health ... for efficacy in reducing symptoms of traumatic stress in cancer patients and ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... planning services to families and entrepreneurs in the Birmingham area, is announcing an ... who needs assistance with her medically challenged son, Anius. , Anius is medically ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Feb. 17, 2017  BioDigital, Inc., creators of ... of their 3D body mapping technology with eClinicalWorks, ... new integration will be used to capture and ... of the human body. BioDigital pilots show using ... while also increasing the precision of clinical annotations ...
(Date:2/17/2017)... -- Noble Capital Markets announced today that it has initiated ... EPIX ). The report was issued by Noble,s Head ... ESSA Pharmaceuticals is a clinical stage biopharmaceutical company ... lead compound EPI-506, is a small molecule oral drug ... receptor, thereby has potential to overcome some of the ...
(Date:2/16/2017)... 16, 2017 Research and Markets has ... Medical Device Technologies" report to their offering. ... Traditional medical ... general instruments, non-drug coated implantables, large endoscopes, needle based drug ... over the last two to three decades for the treatment ...
Breaking Medicine Technology: